Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Cue Biopharma Inc (CUE)
NASDAQ:CUE
CUE Stock Chart & Stats
Day’s Range― - ―
52-Week Range$0.45 - $2.37
Previous CloseN/A
Volume91.78K
Average Volume (3M)240.42K
Market Cap
$86.79M
Enterprise Value$15.88M
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
Beta1.86
Next Earnings
Mar 12, 2025EPS Estimate
-0.09Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.91
Shares Outstanding63,350,327
10 Day Avg. Volume167,139
30 Day Avg. Volume240,418
Standard Deviation0.26
R-Squared0.11
Alpha-0.03
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)9.50
Price to Cash Flow (P/CF)-3.00
P/FCF Ratio0.00
Enterprise Value/Market Cap0.18
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-0.49
Enterprise Value/Ebitda-0.40
Forecast
1Y Price Target
$2.00Price Target Upside45.99% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering0
---
Cue Biopharma News
PremiumCompany Announcements
Cue Biopharma Reports Increased Revenue Amid Ongoing Losses
---
Bulls Say, Bears Say
Bulls Say
Clinical OutcomesCUE-101 in combination with pembrolizumab achieved a significant improvement in overall survival rates in patients with recurrent/metastatic HPV16+ HNSCC.
Pipeline DevelopmentThe CUE-500 series offers a potential off-the-shelf alternative to CAR-T cell therapies, which could generate significant shareholder value.
Strategic PartnershipsThe partnership with Ono Pharmaceuticals for CUE-401 in the autoimmune space holds significant potential, with Cue retaining 50% of the rights in the U.S. market.
Bears Say
Development ChallengesThe presence of confounding variables and lack of a partner may hinder the clinical development progress of CUE-101.
Financial ConstraintsThe cash runway is expected to last until mid-2025, suggesting potential financial constraints if additional partnerships or funding are not secured.
Restructuring ImpactThe restructuring led to the elimination of CUE-101 from valuation, resulting in a lower price target for the company.
---
Ownership Overview
0.52% Insiders
4.10% Mutual Funds
10.58% Other Institutional Investors
81.43% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
CUE FAQ
What was Cue Biopharma Inc’s price range in the past 12 months?
Cue Biopharma Inc lowest stock price was $0.45 and its highest was $2.37 in the past 12 months.
What is Cue Biopharma Inc’s market cap?
Cue Biopharma Inc’s market cap is $86.79M.
When is Cue Biopharma Inc’s upcoming earnings report date?
Cue Biopharma Inc’s upcoming earnings report date is Mar 12, 2025 which is in 18 days.
How were Cue Biopharma Inc’s earnings last quarter?
Cue Biopharma Inc released its earnings results on Nov 14, 2024. The company reported -$0.17 earnings per share for the quarter, beating the consensus estimate of -$0.182 by $0.012.
Is Cue Biopharma Inc overvalued?
According to Wall Street analysts Cue Biopharma Inc’s price is currently Undervalued.
Does Cue Biopharma Inc pay dividends?
Cue Biopharma Inc does not currently pay dividends.
What is Cue Biopharma Inc’s EPS estimate?
Cue Biopharma Inc’s EPS estimate is -0.09.
How many shares outstanding does Cue Biopharma Inc have?
Cue Biopharma Inc has 63,350,327 shares outstanding.
What happened to Cue Biopharma Inc’s price movement after its last earnings report?
Cue Biopharma Inc reported an EPS of -$0.17 in its last earnings report, beating expectations of -$0.182. Following the earnings report the stock price went down -17.333%.
Which hedge fund is a major shareholder of Cue Biopharma Inc?
Currently, no hedge funds are holding shares in CUE
---
Cue Biopharma Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$2.00 (45.99% Upside)
$2.00 (45.99% Upside)
Blogger Sentiment
Bullish
CUE Sentiment 100%
Sector Average 70%
Sector Average 70%
Insider Transactions
Bought Shares
Worth $30.9K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 0.4%
Last 30 Days ▼ 5.0%
Last 30 Days ▼ 5.0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-34.13%
12-Months-Change
Fundamentals
Return on Equity
-131.15%
Trailing 12-Months
Asset Growth
-34.95%
Trailing 12-Months
Company Description
Cue Biopharma Inc
Cue Biopharma, Inc. is a biopharmaceutical company, which engages in the development of a novel and proprietary class of biologic drugs for the selective modulation of the human immune system to treat a broad range of cancers and autoimmune disorders. Its pipeline includes Immuno-oncology, CUE-100 framework, CUE-200 framework, and autoimmune disease. The company was founded on December 31, 2014 and is headquartered in Cambridge, MA.
---
CUE Stock 12 Month Forecast
Average Price Target
$2.00
▲(45.99% Upside)
Technical Analysis
Agenus
―
Fate Therapeutics
―
Affimed
―
Adaptimmune Therapeutics
―
Corvus Pharmaceuticals
―
Best Analysts Covering CUE
1 Year
1 Year Success Rate
5/14 ratings generated profit
1 Year Average Return
-18.19%
reiterated a buy rating 3 months ago
Copying Stephen Willey's trades and holding each position for 1 Year would result in 35.71% of your transactions generating a profit, with an average return of -18.19% per trade.
---